Perspective Therapeutics, Inc.
CATX
$2.99
-$0.13-4.17%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 409.00K | 618.00K | 884.00K | 1.08M | 1.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 409.00K | 618.00K | 884.00K | 1.08M | 1.24M |
| Cost of Revenue | 96.18M | 91.26M | 84.22M | 64.17M | 55.86M |
| Gross Profit | -95.77M | -90.64M | -83.33M | -63.10M | -54.63M |
| SG&A Expenses | 29.46M | 29.38M | 30.23M | 31.53M | 30.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.64M | 120.63M | 114.45M | 95.70M | 86.64M |
| Operating Income | -125.23M | -120.01M | -113.56M | -94.63M | -85.40M |
| Income Before Tax | -117.42M | -112.44M | -104.43M | -108.41M | -97.56M |
| Income Tax Expenses | -793.00K | -793.00K | -793.00K | -- | -- |
| Earnings from Continuing Operations | -116.63 | -111.65 | -103.64 | -106.31 | -95.47 |
| Earnings from Discontinued Operations | 197.00K | 514.00K | 514.00K | 514.00K | 514.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.43M | -111.13M | -103.12M | -105.80M | -94.95M |
| EBIT | -125.23M | -120.01M | -113.56M | -94.63M | -85.40M |
| EBITDA | -121.19M | -116.38M | -110.32M | -91.69M | -82.56M |
| EPS Basic | -1.33 | -1.40 | -1.39 | -1.49 | -1.36 |
| Normalized Basic EPS | -0.84 | -0.88 | -0.88 | -0.72 | -0.64 |
| EPS Diluted | -1.33 | -1.40 | -1.39 | -1.49 | -1.36 |
| Normalized Diluted EPS | -0.84 | -0.88 | -0.88 | -0.72 | -0.64 |
| Average Basic Shares Outstanding | 372.89M | 326.48M | 295.23M | 285.31M | 281.65M |
| Average Diluted Shares Outstanding | 372.89M | 326.48M | 295.23M | 285.31M | 281.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |